Definium Therapeutics, Inc. (DFTX) — Cash Flow-to-Debt Ratio
Definium Therapeutics, Inc. (DFTX) has a Cash Flow-to-Debt Ratio of -0.39x as of December 2025, meaning its operating cash flow of $-41.89 Million could theoretically repay 0% of its total liabilities ($107.77 Million) in one year. See DFTX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Definium Therapeutics, Inc. Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Definium Therapeutics, Inc. across 11 annual periods. Also explore Definium Therapeutics, Inc. (DFTX) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Definium Therapeutics, Inc. (2015–2025)
Year-by-year debt coverage analysis for Definium Therapeutics, Inc.. For market capitalisation and broader financial context, see DFTX stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.22x | $-131.56 Million | $107.77 Million | ▲ +6.4% |
| 2024 | -1.30x | $-79.13 Million | $60.70 Million | ▲ +6.0% |
| 2023 | -1.39x | $-64.36 Million | $46.41 Million | ▲ +47.2% |
| 2022 | -2.63x | $-50.14 Million | $19.08 Million | ▲ +29.2% |
| 2021 | -3.71x | $-45.82 Million | $12.34 Million | ▲ +11.1% |
| 2020 | -4.18x | $-23.60 Million | $5.65 Million | ▼ -299.2% |
| 2019 | -1.05x | $-208.12K | $198.96K | ▲ +98.8% |
| 2018 | -87.79x | $-722.45K | $8.23K | ▼ -960.4% |
| 2017 | -8.28x | $-665.98K | $80.44K | ▼ -2245.8% |
| 2016 | -0.35x | $-26.64K | $75.47K | ▲ +94.3% |
| 2015 | -6.22x | $-46.56K | $7.49K | — |